Key points are not available for this paper at this time.
Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jicheng Lv
King University
Lijun Liu
Anhui Medical University
Chuan‐Ming Hao
University Malaya Medical Centre
Kidney International Reports
Peking University
Shanghai Jiao Tong University
Fudan University
Building similarity graph...
Analyzing shared references across papers
Loading...
Lv et al. (Thu,) studied this question.
synapsesocial.com/papers/69d90348bfc0898f4bd17d79 — DOI: https://doi.org/10.1016/j.ekir.2022.12.014